FDMT vs NPCE: fair value comparison
4D Molecular Therapeutics, Inc. and NeuroPace, Inc. · Updated 2026-10-19
FDMT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NPCE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, FDMT currently ranks higher by quality score.
| FDMT | NPCE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $12.14 | $12.24 |
| 12-month range | $7.19–$16.76 | $9.40–$19.29 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #164 of 301 Healthcare | #166 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: FDMT fair value analysis · NPCE fair value analysis